Back to Report Store Home

Epigenetics Therapeutics to 2017 – High Market Potential for Epigenetics Drugs in Acute Myeloid Leukemia, Multiple Myeloma and Cutaneous T-Cell Lymphoma

  • Published: Jul-2010
  • Report Code: GBIHC039MR
  • Report Format: pdf

Description

List of Tables

Table 1: List of Approved Epigenetic Drugs, 2010

Table 2: Epigenetic Therapeutics Market, Global, Revenue Forecast ($m) 2009–2017

Table 3: Epigenetic Therapeutics Market, by Geography, Revenue Forecast ($m) 2009–2017

Table 4: Epigenetic therapeutics Market, The US, Revenue Forecast ($m) 2009 - 2017

Table 5: Epigenetic Therapeutics Market, Europe, Revenue Forecast ($m), 2009- 2017

Table 6: Epigenetic Therapeutics Market, Japan, Revenue Forecast ($m), 2009–2017

Table 7: Vidaza – Snapshot, 2010

Table 8: Vidaza, Global, Revenue Forecast ($m) 2009–2017

Table 9: Vidaza, By Geography, Revenue Forecast ($m )2009 - 2017

Table 10: Vidaza, The US, Revenue Forecast ($m) 2009–2017

Table 11: Vidaza, Europe, Revenue Forecast ($m), 2009–2017

Table 12: Vidaza, Japan, Revenue Forecast ($m), 2009–2017

Table 13: Vidaza Market Potential, Global, Revenue Forecast ($m) 2012–2017

Table 14: Vidaza Market Potential, By Geography, Revenue Forecast ($m), 2012–2017

Table 15: Vidaza Market Potential, The US, Revenue Forecast ($m), 2012–2017

Table 16: Vidaza Market Potential, Europe, Revenue Forecast ($m), 2012–2017

Table 17: Vidaza Market Potential, Japan, Revenue Forecast ($m), 2012–2017

Table 18: Efficacy of Vidaza in MDS Patients, 2010

Table 19: Dacogen – Snapshot, 2010

Table 20: Dacogen, Global, Revenue Forecast ($m), 2009–2017

Table 21: Dacogen, By Geography, Revenue Forecast ($m), 2009–2017

Table 22: Dacogen, The US, Revenue Forecast ($m), 2009–2017

Table 23: Dacogen, Europe, Revenue Forecast ($m), 2009– 2017

Table 24: Dacogen, Japan, Revenue Forecast ($m), 2009–2017

Table 25: Dacogen, Market Potential, Global, Revenue Forecast ($m), 2012–2017

Table 26: Dacogen Market Potential, By Geography, Revenue Forecast ($m), 2012–2017

Table 27: Dacogen, Market Potential, The US, Revenue Forecast ($m), 2012–2017

Table 28: Dacogen Market Potential, Europe, Revenue Forecast ($m), 2012–2017

Table 29: Dacogen, Market Potential, Japan, Revenue Forecast ($m), 2012–2017

Table 30: Zolinza Snapshot, 2010

Table 31: Zolinza, Global, Revenue Forecast ($m), 2010–2017

Table 32: Zolinza, By Geography, Revenue Forecast ($m), 2010–2017

Table 33: Zolinza, The US, Revenue Forecast ($m), 2010–2017

Table 34: Zolinza, Europe, Revenue Forecast ($m), 2010–2017

Table 35: Zolinza, Japan, Revenue Forecast ($m), 2010–2017

Table 36: Zolinza Market Potential, By Geography, Revenue Forecast ($m), 2012–2017

Table 37: Zolinza, Market Potential, By Geography, Revenue Forecast ($m), 2012–2017

Table 38: Zolinza Market Potential, The US, Revenue Forecast ($m), 2012–2017

Table 39: Zolinza Market Potential, Europe, Revenue Forecast ($m), 2012–2017

Table 40: Zolinza Market Potential, Japan, Revenue Forecast ($m), 2012–2017

Table 41: Istodax Snapshot, 2010

Table 42: Istodax Market Potential, By Geography, Revenue Forecast ($m), 2010–2017

Table 43: Istodax Market Potential, By Geography, Revenue Forecast ($m), 2012–2017

Table 44: Istodax Market Potential, The US, Revenue Forecast ($m), 2010–2017

Table 45: Istodax Market Potential, Europe, Revenue Forecast ($m), 2010–2017

Table 46: Istodax Market Potential, The US, Revenue Forecast ($m), 2010–2017

License Details
Electronic PDF copy delivered via email. Report can be used by individual purchaser only.
Single User Licence
$3500
Electronic PDF copy delivered via email. Report can be shared by unlimited users within one corporate location, e.g. a regional office.
Site Licence
$7000
Electronic PDF copy delivered via email. Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company.
Global Licence
$10500
Email to a colleague Enquire Before Buying
Prefer to speak to a team member? Call us on:
+44 161 359 5414
Or click here to contact us
Secure Payments
Cards